Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer

Clinical Cancer Research

Volumn 15, Issue 22, 2009, Pages 7099-7105

  Taplin, Mary Ellen ^a,b,c,e   Regan, Meredith M ^a,b,c   Ko, Yoo Joung ^f   Bubley, Glenn J ^b,c,d,e   Duggan, Stephen E ^d   Werner, Lillian ^a,c   Beer, Tomasz M ^e,g   Ryan, Christopher W ^e,g   Mathew, Paul ^e,h   Tu, Shi Ming ^e,h   Denmeade, Samuel R ^e,i   Oh, William K ^a,b,c,e   Sartor, Oliver ^a,j   Mantzoros, Christos S ^b,d   Rittmaster, Roger ^k   Kantoff, Philip W ^a,b,c,e   Balk, Steven P ^b,c,d,e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER HARVARD CANCER CENTER   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e Department of Defense Prostate Cancer Clinical Trials Consortium ^*  (United States)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ANDROSTENEDIONE; BICALUTAMIDE; DUTASTERIDE; ESTRAMUSTINE; FINASTERIDE; FLUTAMIDE; HYDROCORTISONE; KETOCONAZOLE; NILUTAMIDE; PRASTERONE SULFATE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANDROGEN SYNTHESIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLADDER BLEEDING; CANCER GROWTH; CASTRATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG ERUPTION; DRUG WITHDRAWAL; DYSPNEA; HORMONE INHIBITION; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; IMPOTENCE; INFECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; URINARY FREQUENCY; URINARY URGENCY; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; ANDROGENS; AZASTEROIDS; CHOLESTENONE 5 ALPHA-REDUCTASE; HUMANS; HYDROCORTISONE; KETOCONAZOLE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE; TREATMENT OUTCOME;

EID: 72549108829     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1722     Document Type: Article

References (30)

1. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-8261
2. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen- responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164: 217-227 (Pubitemid 38364606)
3. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66:2815-2825
4. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9:401-406
5. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-1398
6. Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999;59:2511-2515 (Pubitemid 29269089)
7. Gregory CW, He B, Johnson RT, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315-4319
8. Agoulnik IU, Vaid A, Nakka M, et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 2006;66:10594-10602
9. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase [see comments]. Nat Med 1999;5:280-285 (Pubitemid 29124362)
10. Weber MJ, Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 2004;91: 13-25.
11. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004;6:517-527
12. Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci U S A 2006;103: 15969-15974 (Pubitemid 44657576)
13. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-4454
14. Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castrationresistant prostate cancer. Cancer Res 2008;68: 6407-6415
15. Geller J, Albert JD, Nachtsheim DA, Loza D. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol 1984;132:693-696
16. Mohler JL, Gregory CW, Ford OH III, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-448 (Pubitemid 38173980)
17. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653-4657
18. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-1042
19. Joyce R, Fenton MA, Rode P, et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998;159:149-153 (Pubitemid 27525592)
20. Scher HI, Liebertz C, Kelly WK, et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997;15:2928-2938
21. Mahoney EM, Harrison JH. Bilateral adrenalectomy for palliative treatment of prostatic cancer. J Urol 1972;108:936-938
22. Yap TA, Carden CP, Attard G, de Bono JS. Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol 2008;8:449-457
23. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22:1025-1033 (Pubitemid 41095034)
24. Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a Cancer and Leukemia Group B study. Clin Cancer Res 2007;13:2030-2037
25. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563-4571
26. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224 (Pubitemid 36859473)
27. Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ. Type 1 and type 2 5α-reductase expression in the development and progression of prostate cancer. Eur Urol 2008;53:244-252
28. Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology 2008;72: 808-812
29. Bubley GJ, Carducci M, DahutW, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-3467
30. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-3748